Limits...
Meta-analysis of the aldehyde dehydrogenases-2 (ALDH2) Glu487Lys polymorphism and colorectal cancer risk.

Zhao H, Liu KJ, Lei ZD, Lei SL, Tian YQ - PLoS ONE (2014)

Bottom Line: GG analysis (OR = 0.74, 95%CI = 0.52-1.06,p = 0.11) and the recessive genetic model analysis (OR = 0.86, 95%CI = 0.69-1.07, p = 0.17).Cumulative meta-analysis based on publication time confirmed these findings.Our results suggested that the ALDH2 Glu487Lys polymorphism may be associated with a decreased risk of colorectal cancer.

View Article: PubMed Central - PubMed

Affiliation: School of Public Health, Central South University, Changsha, China ; Department of General Surgery, the Second Xiangya Hospital, Central South University, Changsha, China.

ABSTRACT
A number of studies have explored the association of the aldehyde dehydrogenases-2 (ALDH2) Glu487Lys polymorphism and risk of colorectal cancer; however, the results are inconsistent. We performed this meta-analysis to clarify this issue using all the available evidence. Relevant studies were retrieved by searching PubMed. Eleven case-control studies were included in the meta-analysis, representing 2909 cases and 4903 controls. The pooled results based on all included studies showed a decreased colorectal cancer risk in the analysis of the GA genotype vs. the GG genotype (OR = 0.81, 95%CI = 0.68-0.98, p = 0.03) and in the dominant genetic model analysis (OR = 0.81, 95%CI = 0.67-0.98, p = 0.03). However, there was no statistical difference in the AA vs. GG analysis (OR = 0.74, 95%CI = 0.52-1.06,p = 0.11) and the recessive genetic model analysis (OR = 0.86, 95%CI = 0.69-1.07, p = 0.17). Cumulative meta-analysis based on publication time confirmed these findings. Patients with colorectal cancer had a higher frequency of the GG genotype (OR = 1.10, 95% CI = 1.02-1.20, p = 0.02) and a lower frequency of the GA genotype (OR = 0.89, 95%CI = 0.81-0.98, p = 0.02) comparing with control population. Our results suggested that the ALDH2 Glu487Lys polymorphism may be associated with a decreased risk of colorectal cancer.

Show MeSH

Related in: MedlinePlus

Flowchart of the study selection.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3928247&req=5

pone-0088656-g001: Flowchart of the study selection.

Mentions: Figure 1 shows the detailed selection procedure. Thirty articles were retrieved from PubMed, fifteen of which were excluded after screening the titles and abstracts (six were irrelevant studies and nine were reviews or meta-analyses). Fifteen relevant articles were selected for detailed assessment by reading the full text. Four of these were excluded (Yin's study [27] and Otani's study [28] had no usable data and Landi's study[29] and Ferrari's study[30] were not about the rs671 polymorphism). Finally, eleven studies met the inclusion criteria (comprising 2909 cases and 4903 controls). Genotype distributions in the controls of Chiang's study[15] and Miyasaka's syudy[16] were not in agreement with the HWE. The detailed characteristics of the studies are shown in Table 1.


Meta-analysis of the aldehyde dehydrogenases-2 (ALDH2) Glu487Lys polymorphism and colorectal cancer risk.

Zhao H, Liu KJ, Lei ZD, Lei SL, Tian YQ - PLoS ONE (2014)

Flowchart of the study selection.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3928247&req=5

pone-0088656-g001: Flowchart of the study selection.
Mentions: Figure 1 shows the detailed selection procedure. Thirty articles were retrieved from PubMed, fifteen of which were excluded after screening the titles and abstracts (six were irrelevant studies and nine were reviews or meta-analyses). Fifteen relevant articles were selected for detailed assessment by reading the full text. Four of these were excluded (Yin's study [27] and Otani's study [28] had no usable data and Landi's study[29] and Ferrari's study[30] were not about the rs671 polymorphism). Finally, eleven studies met the inclusion criteria (comprising 2909 cases and 4903 controls). Genotype distributions in the controls of Chiang's study[15] and Miyasaka's syudy[16] were not in agreement with the HWE. The detailed characteristics of the studies are shown in Table 1.

Bottom Line: GG analysis (OR = 0.74, 95%CI = 0.52-1.06,p = 0.11) and the recessive genetic model analysis (OR = 0.86, 95%CI = 0.69-1.07, p = 0.17).Cumulative meta-analysis based on publication time confirmed these findings.Our results suggested that the ALDH2 Glu487Lys polymorphism may be associated with a decreased risk of colorectal cancer.

View Article: PubMed Central - PubMed

Affiliation: School of Public Health, Central South University, Changsha, China ; Department of General Surgery, the Second Xiangya Hospital, Central South University, Changsha, China.

ABSTRACT
A number of studies have explored the association of the aldehyde dehydrogenases-2 (ALDH2) Glu487Lys polymorphism and risk of colorectal cancer; however, the results are inconsistent. We performed this meta-analysis to clarify this issue using all the available evidence. Relevant studies were retrieved by searching PubMed. Eleven case-control studies were included in the meta-analysis, representing 2909 cases and 4903 controls. The pooled results based on all included studies showed a decreased colorectal cancer risk in the analysis of the GA genotype vs. the GG genotype (OR = 0.81, 95%CI = 0.68-0.98, p = 0.03) and in the dominant genetic model analysis (OR = 0.81, 95%CI = 0.67-0.98, p = 0.03). However, there was no statistical difference in the AA vs. GG analysis (OR = 0.74, 95%CI = 0.52-1.06,p = 0.11) and the recessive genetic model analysis (OR = 0.86, 95%CI = 0.69-1.07, p = 0.17). Cumulative meta-analysis based on publication time confirmed these findings. Patients with colorectal cancer had a higher frequency of the GG genotype (OR = 1.10, 95% CI = 1.02-1.20, p = 0.02) and a lower frequency of the GA genotype (OR = 0.89, 95%CI = 0.81-0.98, p = 0.02) comparing with control population. Our results suggested that the ALDH2 Glu487Lys polymorphism may be associated with a decreased risk of colorectal cancer.

Show MeSH
Related in: MedlinePlus